Market Place
Sourcing Support
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active (pJIA)
11 Jun 2024 //
GLOBENEWSWIRE
Sanofi Synthelabo Biologic Sarilumab Receives Approval in US
10 Jun 2024 //
FDA
US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
02 Mar 2023 //
PHARMACEUTICAL TECHNOLOGY
Kevzara Approved by FDA as First Biologic Indicated for Polymyalgia Rheumatica
28 Feb 2023 //
GLOBENEWSWIRE
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
13 Oct 2021 //
PRESS RELEASE
MSF demands newest COVID-19 treatment recommended by WHO accessible to all
27 Sep 2021 //
EXPRESS PHARMA
Tocilizumab and sarilumab cut risk of death in severe COVID-19 patients
08 Jan 2021 //
PHARMATIMES
UK study shows arthritis drugs could improve survival in Covid-19 patients
08 Jan 2021 //
PHARMACEUTICAL-TECHNOLOGY
Two drugs found to reduce mortality in severe COVID-19 patients
07 Jan 2021 //
PMLIVE
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5
07 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy Featured
17 Sep 2020 //
BIOSPACE
After another Kevzara fail in COVID-19, Sanofi and Regeneron shift their attention elsewhere
02 Sep 2020 //
FIERCE PHARMA
Roche, Regeneron join forces to more than triple manufacturing of COVID-19
19 Aug 2020 //
FIERCEPHARMA
Sanofi halts trials of IL-6 drug for Covid-19, India to continue with trial
07 Jul 2020 //
ECONOMICTIMES
Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients
04 Jul 2020 //
REUTERS
Sanofi, Regeneron`s Kevzara fails late-stage study in COVID-19
03 Jul 2020 //
MARKETWATCH
Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial
02 Jul 2020 //
PRNEWSWIRE
Arthritis Drug Seen Helping Covid-19 Patients in Small Study
07 May 2020 //
BNNBLOOMBERG
Regeneron ramps up COVID-19 antibody supply ahead of human tests
05 May 2020 //
FIERCE PHARMA
Regeneron, Sanofi to treat only `critical` COVID-19 patients with arthritis drug
28 Apr 2020 //
REUTERS
Sanofi CEO cautions arthritis drug a `long shot` in COVID-19
24 Apr 2020 //
BIOPHARMADIVE
Pharma lost 8% in market value in Q1 amid COVID-19: report
23 Apr 2020 //
FIERCE PHARMA
Sanofi, Regeneron pump the brakes on reworked Kevzara deal
09 Apr 2020 //
FIERCE PHARMA
Sanofi and Regeneron Launch Second Kevzara Trial Against COVID-19
01 Apr 2020 //
BIOSPACE
Sanofi, Regeneron launch Kevzara coronavirus study outside U.S.
31 Mar 2020 //
FIERCE PHARMA
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
17 Mar 2020 //
PR NEWSWIRE
FDA requires new health warnings for cigarette packages and advertisements
17 Mar 2020 //
PR NEWSWIRE
Sanofi, Regeneron begin testing arthritis drug as coronavirus treatment
17 Mar 2020 //
ECONOMICTIMES
Sanofi, Regeneron roll Kevzara into COVID-19 trials immediately
17 Mar 2020 //
PR NEWSWIRE
Could arthritis med Kevzara hold promise against the novel coronavirus
12 Mar 2020 //
FIERCE PHARMA
Regeneron to lay off field staff as it rejigs Sanofi partnership
03 Jan 2020 //
FIERCE PHARMA
Can Dupixent steal half of a $21B eczema market? Not so fast
12 Dec 2019 //
FIERCE PHARMA
Sanofi and Regeneron to simplify antibody partnership
12 Dec 2019 //
PHARMACEUTICAL-TECHNOLOGY
GSK launches PhIII programme for otilimab in RA
06 Jul 2019 //
PHARMATIMES
Sanofi to continue with cost-cutting as new drugs show promise
18 Sep 2018 //
PHARMA PHORUM
Regeneron continues New York expansion with $800M project, 1,500 jobs
13 Sep 2018 //
FIERCE PHARMA
US Rheumatologists` Early Views on Eli Lilly`s Olumiant for RA
20 Aug 2018 //
PR NEWSWIRE
Regeneron plots DTC advertising and discount push to put Eylea back on track
04 Aug 2018 //
FIERCE PHARMA
